The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
NetMHCpan-4.0: Improved Peptide–MHC Class I Interaction Predictions Integrating Eluted Ligand and Peptide Binding Affinity Data
Open accessAbstract
Cytotoxic T cells are of central importance in the immune system’s response to disease. They recognize defective cells by binding to peptides presented on the cell surface by MHC class I molecules. Peptide binding to MHC molecules is the single most selective step in the Ag-presentation pathway. Therefore, in the quest for T cell epitopes, the prediction of peptide binding to MHC molecules has attracted widespread attention. In the past, predictors of peptide–MHC interactions have primarily been trained on binding affinity data. Recently, an increasing number of MHC-presented peptides identified by mass spectrometry have been reported containing information about peptide-processing steps in the presentation pathway and the length distribution of naturally presented peptides. In this article, we present NetMHCpan-4.0, a method trained on binding affinity and eluted ligand data leveraging the information from both data types. Large-scale benchmarking of the method demonstrates an increase in predictive performance compared with state-of-the-art methods when it comes to identification of naturally processed ligands, cancer neoantigens, and T cell epitopes.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Mutant MHC class II epitopes drive therapeutic immune responses to cancer
Kreiter, S., Vormehr, M., van de Roemer, N., Diken, M., Löwer, M., Diekmann, J., Boegel, S., Schrörs, B., Vascotto, F., Castle, J. C., et al. (2015) · Nature · doi:10.1038/nature14426 · Cited by 1,243
Cited by
Grifoni, A., Weiskopf, D., Ramirez, S. I., Mateus, J., Dan, J. M., Moderbacher, C. R., Rawlings, S. A., Sutherland, A., Premkumar, L., Jadi, R. S., et al. (2020) · Cell · doi:10.1016/j.cell.2020.05.015 · Cited by 3,595
Self-citationReynisson, B., Alvarez, B., Paul, S., Peters, B., & Nielsen, M. (2020) · Nucleic Acids Research · doi:10.1093/nar/gkaa379 · Cited by 2,361
Self-citationBraun, D. A., Hou, Y., Bakouny, Z., Ficial, M., Sant’ Angelo, M., Forman, J., Ross-Macdonald, P., Berger, A. C., Jegede, O. A., Elagina, L., et al. (2020) · Nature Medicine · doi:10.1038/s41591-020-0839-y · Cited by 992
Advances in the development of personalized neoantigen-based therapeutic cancer vaccines
Blass, E., & Ott, P. A. (2021) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-020-00460-2 · Cited by 1,042
Neoantigens: promising targets for cancer therapy
Xie, N., Shen, G., Gao, W., Huang, Z., Huang, C., & Fu, L. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-01270-x · Cited by 1,020
Macromolecular modeling and design in Rosetta: recent methods and frameworks
Leman, J. K., Weitzner, B. D., Lewis, S. M., Adolf-Bryfogle, J., Alam, N., Alford, R. F., Aprahamian, M., Baker, D., Barlow, K. A., Barth, P., et al. (2020) · Nature Methods · doi:10.1038/s41592-020-0848-2 · Cited by 888
Proteogenomic Characterization Reveals Therapeutic Vulnerabilities in Lung Adenocarcinoma
Gillette, M. A., Satpathy, S., Cao, S., Dhanasekaran, S. M., Vasaikar, S. V., Krug, K., Petralia, F., Li, Y., Liang, W.-W., Reva, B., et al. (2020) · Cell · doi:10.1016/j.cell.2020.06.013 · Cited by 820
MHC-II neoantigens shape tumour immunity and response to immunotherapy
Alspach, E., Lussier, D. M., Miceli, A. P., Kizhvatov, I., DuPage, M., Luoma, A. M., Meng, W., Lichti, C. F., Esaulova, E., Vomund, A. N., et al. (2019) · Nature · doi:10.1038/s41586-019-1671-8 · Cited by 846
Proteogenomic Analysis of Human Colon Cancer Reveals New Therapeutic Opportunities
Vasaikar, S., Huang, C., Wang, X., Petyuk, V. A., Savage, S. R., Wen, B., Dou, Y., Zhang, Y., Shi, Z., Arshad, O. A., et al. (2019) · Cell · doi:10.1016/j.cell.2019.03.030 · Cited by 799
Integrated Proteogenomic Characterization of Clear Cell Renal Cell Carcinoma
Clark, D. J., Dhanasekaran, S. M., Petralia, F., Pan, J., Song, X., Hu, Y., da Veiga Leprevost, F., Reva, B., Lih, T.-S. M., Chang, H.-Y., et al. (2019) · Cell · doi:10.1016/j.cell.2019.10.007 · Cited by 730
Tarke, A., Sidney, J., Methot, N., Yu, E. D., Zhang, Y., Dan, J. M., Goodwin, B., Rubiro, P., Sutherland, A., Wang, E., et al. (2021) · Cell Reports Medicine · doi:10.1016/j.xcrm.2021.100355 · Cited by 706
Self-citationTarke, A., Sidney, J., Kidd, C. K., Dan, J. M., Ramirez, S. I., Yu, E. D., Mateus, J., da Silva Antunes, R., Moore, E., Rubiro, P., et al. (2021) · Cell Reports Medicine · doi:10.1016/j.xcrm.2021.100204 · Cited by 540
Self-citationSARS-CoV-2-derived peptides define heterologous and COVID-19-induced T cell recognition
Nelde, A., Bilich, T., Heitmann, J. S., Maringer, Y., Salih, H. R., Roerden, M., Lübke, M., Bauer, J., Rieth, J., Wacker, M., et al. (2021) · Nature Immunology · doi:10.1038/s41590-020-00808-x · Cited by 582
Proteogenomic Characterization of Endometrial Carcinoma
Dou, Y., Kawaler, E. A., Cui Zhou, D., Gritsenko, M. A., Huang, C., Blumenberg, L., Karpova, A., Petyuk, V. A., Savage, S. R., Satpathy, S., et al. (2020) · Cell · doi:10.1016/j.cell.2020.01.026 · Cited by 485
Identifying and Targeting Human Tumor Antigens for T Cell-Based Immunotherapy of Solid Tumors
Leko, V., & Rosenberg, S. A. (2020) · Cancer Cell · doi:10.1016/j.ccell.2020.07.013 · Cited by 449
O’Donnell, T. J., Rubinsteyn, A., & Laserson, U. (2020) · Cell Systems · doi:10.1016/j.cels.2020.06.010 · Cited by 440
IEDB-AR: immune epitope database-analysis resource in 2019
Dhanda, S. K., Mahajan, S., Paul, S., Yan, Z., Kim, H., Jespersen, M. C., Jurtz, V., Andreatta, M., Greenbaum, J. A., Marcatili, P., et al. (2019) · Nucleic Acids Research · doi:10.1093/nar/gkz452 · Cited by 427
Endogenous retroviral signatures predict immunotherapy response in clear cell renal cell carcinoma
Smith, C. C., Beckermann, K. E., Bortone, D. S., De Cubas, A. A., Bixby, L. M., Lee, S. J., Panda, A., Ganesan, S., Bhanot, G., Wallen, E. M., et al. (2018) · Journal of Clinical Investigation · doi:10.1172/jci121476 · Cited by 303
Deep learning-based prediction of the T cell receptor–antigen binding specificity
Lu, T., Zhang, Z., Zhu, J., Wang, Y., Jiang, P., Xiao, X., Bernatchez, C., Heymach, J. V., Gibbons, D. L., Wang, J., et al. (2021) · Nature Machine Intelligence · doi:10.1038/s42256-021-00383-2 · Cited by 295
Freed-Pastor, W. A., Lambert, L. J., Ely, Z. A., Pattada, N. B., Bhutkar, A., Eng, G., Mercer, K. L., Garcia, A. P., Lin, L., Rideout, W. M., et al. (2021) · Cancer Cell · doi:10.1016/j.ccell.2021.07.007 · Cited by 273
An in silico deep learning approach to multi-epitope vaccine design: a SARS-CoV-2 case study
Yang, Z., Bogdan, P., & Nazarian, S. (2021) · Scientific Reports · doi:10.1038/s41598-021-81749-9 · Cited by 271
Woolston, A., Khan, K., Spain, G., Barber, L. J., Griffiths, B., Gonzalez-Exposito, R., Hornsteiner, L., Punta, M., Patil, Y., Newey, A., et al. (2019) · Cancer Cell · doi:10.1016/j.ccell.2019.05.013 · Cited by 254
Marcu, A., Bichmann, L., Kuchenbecker, L., Kowalewski, D. J., Freudenmann, L. K., Backert, L., Mühlenbruch, L., Szolek, A., Lübke, M., Wagner, P., et al. (2021) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2020-002071 · Cited by 250
Artificial Intelligence in Oncology: Current Landscape, Challenges, and Future Directions
Lotter, W., Hassett, M. J., Schultz, N., Kehl, K. L., Van Allen, E. M., & Cerami, E. (2024) · Cancer Discovery · doi:10.1158/2159-8290.cd-23-1199 · Cited by 196
Pan-cancer analysis identifies tumor-specific antigens derived from transposable elements
Shah, N. M., Jang, H. J., Liang, Y., Maeng, J. H., Tzeng, S.-C., Wu, A., Basri, N. L., Qu, X., Fan, C., Li, A., et al. (2023) · Nature Genetics · doi:10.1038/s41588-023-01349-3 · Cited by 175
Xu, Y., Su, G.-H., Ma, D., Xiao, Y., Shao, Z.-M., & Jiang, Y.-Z. (2021) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-021-00729-7 · Cited by 163
Chiou, S.-H., Tseng, D., Reuben, A., Mallajosyula, V., Molina, I. S., Conley, S., Wilhelmy, J., McSween, A. M., Yang, X., Nishimiya, D., et al. (2021) · Immunity · doi:10.1016/j.immuni.2021.02.014 · Cited by 133
Gangaev, A., Ketelaars, S. L. C., Isaeva, O. I., Patiwael, S., Dopler, A., Hoefakker, K., De Biasi, S., Gibellini, L., Mussini, C., Guaraldi, G., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-22811-y · Cited by 111
Identification of antigens presented by MHC for vaccines against tuberculosis
Bettencourt, P., Müller, J., Nicastri, A., Cantillon, D., Madhavan, M., Charles, P. D., Fotso, C. B., Wittenberg, R., Bull, N., Pinpathomrat, N., et al. (2020) · npj Vaccines · doi:10.1038/s41541-019-0148-y · Cited by 110
Stopfer, L. E., Mesfin, J. M., Joughin, B. A., Lauffenburger, D. A., & White, F. M. (2020) · Nature Communications · doi:10.1038/s41467-020-16588-9 · Cited by 109
Rapid idiosyncratic mechanisms of clinical resistance to KRAS G12C inhibition
Tsai, Y. S., Woodcock, M. G., Azam, S. H., Thorne, L. B., Kanchi, K. L., Parker, J. S., Vincent, B. G., & Pecot, C. V. (2022) · Journal of Clinical Investigation · doi:10.1172/jci155523 · Cited by 103
Dynamically evolving novel overlapping gene as a factor in the SARS-CoV-2 pandemic
Nelson, C. W., Ardern, Z., Goldberg, T. L., Meng, C., Kuo, C.-H., Ludwig, C., Kolokotronis, S.-O., & Wei, X. (2020) · eLife · doi:10.7554/elife.59633 · Cited by 87
Yang, B., Li, X., Zhang, W., Fan, J., Zhou, Y., Li, W., Yin, J., Yang, X., Guo, E., Li, X., et al. (2022) · Cell Reports Medicine · doi:10.1016/j.xcrm.2022.100856 · Cited by 84
Entinostat induces antitumor immune responses through immune editing of tumor neoantigens
Truong, A. S., Zhou, M., Krishnan, B., Utsumi, T., Manocha, U., Stewart, K. G., Beck, W., Rose, T. L., Milowsky, M. I., He, X., et al. (2021) · Journal of Clinical Investigation · doi:10.1172/jci138560 · Cited by 84
Evolution of Cancer Vaccines—Challenges, Achievements, and Future Directions
Tay, B. Q., Wright, Q., Ladwa, R., Perry, C., Leggatt, G., Simpson, F., Wells, J. W., Panizza, B. J., Frazer, I. H., & Cruz, J. L. G. (2021) · Vaccines · doi:10.3390/vaccines9050535 · Cited by 76
Creating MHC-Restricted Neoantigens with Covalent Inhibitors That Can Be Targeted by Immune Therapy
Hattori, T., Maso, L., Araki, K. Y., Koide, A., Hayman, J., Akkapeddi, P., Bang, I., Neel, B. G., & Koide, S. (2023) · Cancer Discovery · doi:10.1158/2159-8290.cd-22-1074 · Cited by 72
Solleder, M., Guillaume, P., Racle, J., Michaux, J., Pak, H.-S., Müller, M., Coukos, G., Bassani-Sternberg, M., & Gfeller, D. (2020) · Molecular & Cellular Proteomics · doi:10.1074/mcp.tir119.001641 · Cited by 68
van den Bulk, J., Verdegaal, E. M. E., Ruano, D., Ijsselsteijn, M. E., Visser, M., van der Breggen, R., Duhen, T., van der Ploeg, M., de Vries, N. L., Oosting, J., et al. (2019) · Genome Medicine · doi:10.1186/s13073-019-0697-8 · Cited by 63
Pilot study of bempegaldesleukin in combination with nivolumab in patients with metastatic sarcoma
D’Angelo, S. P., Richards, A. L., Conley, A. P., Woo, H. J., Dickson, M. A., Gounder, M., Kelly, C., Keohan, M. L., Movva, S., Thornton, K., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-30874-8 · Cited by 60
Zhang, B., & Bassani-Sternberg, M. (2023) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2023-007073 · Cited by 44
Challenges targeting cancer neoantigens in 2021: a systematic literature review
Chen, I., Chen, M. Y., Goedegebuure, S. P., & Gillanders, W. E. (2021) · Expert Review of Vaccines · doi:10.1080/14760584.2021.1935248 · Cited by 39
Jammihal, T., Saliby, R. M., Labaki, C., Soulati, H., Gallegos, J., Peris, A., McCurry, D., Yu, C., Shah, V., Poduval, D., et al. (2025) · Nature Cancer · doi:10.1038/s43018-024-00896-w · Cited by 38
Siwek, J. C., Omelchenko, A. A., Chhibbar, P., Arshad, S., Rosengart, A., Nazarali, I., Patel, A., Nazarali, K., Rahimikollu, J., Tilstra, J. S., et al. (2025) · Nature Methods · doi:10.1038/s41592-025-02723-1 · Cited by 27
Gupta, S., Nerli, S., Kutti Kandy, S., Mersky, G. L., & Sgourakis, N. G. (2023) · Nature Communications · doi:10.1038/s41467-023-42163-z · Cited by 26
Sun, Y., Florio, T. J., Gupta, S., Young, M. C., Marshall, Q. F., Garfinkle, S. E., Papadaki, G. F., Truong, H. V., Mycek, E., Li, P., et al. (2023) · Science Immunology · doi:10.1126/sciimmunol.adj5792 · Cited by 19
Geometric deep learning improves generalizability of MHC-bound peptide predictions
(2024) · doi:10.1038/s42003-024-07292-1 · Cited by 18
Kelly, J. J., Bloodworth, N., Shao, Q., Shabanowitz, J., Hunt, D., Meiler, J., & Pires, M. M. (2024) · ACS Chemical Biology · doi:10.1021/acschembio.4c00312 · Cited by 15
GraphMHC: Neoantigen prediction model applying the graph neural network to molecular structure
Jeong, H., Cho, Y.-R., Gim, J., Cha, S.-K., Kim, M., & Kang, D. R. (2024) · PLOS ONE · doi:10.1371/journal.pone.0291223 · Cited by 14
Reliable machine learning models in genomic medicine using conformal prediction
Papangelou, C., Kyriakidis, K., Natsiavas, P., Chouvarda, I., & Malousi, A. (2025) · Frontiers in Bioinformatics · doi:10.3389/fbinf.2025.1507448 · Cited by 12
Broadly applicable TCR-based therapy for multiple myeloma targeting the immunoglobulin J chain
Meeuwsen, M. H., Wouters, A. K., Wachsmann, T. L. A., Hagedoorn, R. S., Kester, M. G. D., Remst, D. F. G., van der Steen, D. M., de Ru, A. H., van Hees, E. P., Kremer, M., et al. (2023) · Journal of Hematology & Oncology · doi:10.1186/s13045-023-01408-6 · Cited by 12
Chemical Strategy and AI-Enabled Peptide Vaccine Development
Wang, X.-X., Su, J.-Y., & Li, Y.-M. (2026) · JACS Au · doi:10.1021/jacsau.6c00008 · Cited by 5
Transformers meets neoantigen detection: a systematic literature review
Machaca, V., Goyzueta, V., Cruz, M. G., Sejje, E., Pilco, L. M., López, J., & Túpac, Y. (2024) · Journal of Integrative Bioinformatics · doi:10.1515/jib-2023-0043 · Cited by 5
Structural changes from wild-type define tumor-rejecting neoantigens
Adams, A. C., Macy, A. M., Borden, E. S., Herrmann, L. M., Brambley, C. A., Sonar, S. A., Ma, T., Li, X., Hughes, A., Roe, D. J., et al. (2025) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2025-013148 · Cited by 4
Gupta, S., Nerli, S., Kandy, S. K., Mersky, G. L., & Sgourakis, N. G. (2023) · doi:10.1101/2023.03.20.533510 · Cited by 2
Metadata
- Authors
- Jurtz, V., Paul, S., Andreatta, M., Marcatili, P., Peters, B., & Nielsen, M.
- Venue
- The Journal of Immunology
- Publisher
- Oxford University Press (OUP)
- Published
- 2017-11-01
- Volume
- 199
- Issue
- 9
- Pages
- 3360-3368
- ISSN
- 0022-1767 (ISSN-L)
- 1550-6606
- OpenAlex
- W2953065444
- Cited by
- 1,470
- References
- 1
- FWCI
- 40.76
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.
